Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
Retrieved on:
Wednesday, June 28, 2023
Neutropenia, Society, Bleeding, SNMMI, Civil service commission, ODD, Multiple myeloma, Primary central nervous system lymphoma, Molecular imaging, DCR, Diabetic neuropathy, Cancer, CBR, PFS, MCI, Radiation, Hematological Cancer Research Investment and Education Act, TAD, Macroglobulinemia, European Commission, MD, Patient, Anemia, Cytopenia, Annual general meeting, MM, Arrhythmia, Poster, FDA, Proteasome inhibitor, Thrombocytopenia, ORR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, BCMA, Pharmaceutical industry, Tissue paper, Mineral wool
FLORHAM PARK, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced it presented data at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting from 64 evaluable, relapsed, or refractory multiple myeloma (MM) patients in which iopofosine I 131 demonstrated an overall response rate (ORR) of 28%, a clinical benefit rate (CBR) of 70% and a disease control rate (DCR) of 92%.
Key Points:
- “Our first-in-class targeted radiotherapy, iopofosine I 131, continues to deliver impressive results in patients with hematologic cancers.
- Currently, there is a significant unmet need for patients with refractory multiple myeloma, who essentially have no treatment options once previous therapies stop working,” said Andrei Shustov, MD, senior vice president, medical.
- The oral presentation highlighted data demonstrating the outcomes from two dose levels (60 mCi total administered dose) across these highly refractory patients.
- A copy of the poster is available on the Posters and Publications section of the company’s website.